Health
Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients – Healio
Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant…
Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant and hematopoietic-cell transplant recipients, according to a study published in Open Forum Infectious Diseases.
“Solid-organ and…
Continue Reading
